POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA
Author(s): ,
Cecile Gruchet
Affiliations:
CHU Poitiers,Poitiers,France
,
Stephanie Guidez
Affiliations:
CHU Poitiers,Poitiers,France
,
Cécile Tomowiak
Affiliations:
CHU Poitiers,Poitiers,France
,
Guillemette Fouquet
Affiliations:
CHU Lilles,Lilles,France
,
Antoine Machet
Affiliations:
CHU Poitiers,Poitiers,France
,
Niels Moya
Affiliations:
CHU Poitiers,Poitiers,France
,
Florence Sabirou
Affiliations:
CHU Poitiers,Poitiers,France
,
Anthony Levy
Affiliations:
CHU Poitiers,Poitiers,France
,
Arthur Bobin
Affiliations:
CHU Poitiers,Poitiers,France
,
Helene Gardeney
Affiliations:
CHU Poitiers,Poitiers,France
,
Sabrina Bouyer
Affiliations:
CHU Poitiers,Poitiers,France
,
Franck Bridoux
Affiliations:
CHU Poitiers,Poitiers,France
,
Vincent Javaugue
Affiliations:
CHU Poitiers,Poitiers,France
,
Isabelle Azais
Affiliations:
CHU Poitiers,Poitiers,France
,
Geraldine Durand
Affiliations:
CHU Poitiers,Poitiers,France
,
Herve Avet Loiseau
Affiliations:
CHU Poitiers,Poitiers,France
Xavier Leleu
Affiliations:
CHU Poitiers,Poitiers,France
EHA Library. Gruchet C. Jun 15, 2019; 267029; PS1412
Cecile Gruchet
Cecile Gruchet
Contributions
Abstract

Abstract: PS1412

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background
Pomalidomide in association with dexamethasone is approved for relapsed and refractory Mutiple Myeloma (RRMM) in 3rd line and beyond based on the multicenter international phase 3MM-003 study that demonstrated greater efficacy for Pomalidomide plus dexamethasone over high dose dexamethasone. However, MM-003 mainly recruited RRMM with 5 prior lines +, and very few data are available regarding real life Pomalidomide-based treatment in 3rd and 4th line RRMM.

Aims
The aim of this study was to study efficacy and safety of Pomalidomide-based treatment in 3rd and 4th line for RRMM.

Methods
This study is a retrospective, multicenter study based on 108 consecutive RRMM treated with Pomalidomide-based treatment in 3rd and 4th line. All assessment made according to IMWG.

Results
Median age was 62.5 (range, 30-86), with 36% older than 65 years, sex ratio M/F 1.25 and ISS disease stage 2 or 3 in 58%. 100% patients received previous treatment with Bortezomib and Lenalidomide and 34,2% had previously an autologous stem cell transplantation. 52 patients (48%) had pomalidomide-based therapy as 3rd, and 56 (52%) as 4th line. 74% of patients received a double-based therapy (Pomalidomide plus Dexamethasone) and 26% received a triple based therapy (Pomalidomide, Cyclophosphamide and Dexamethasone). Overall ORR was 55%, with 25% more than VGPR including 3 complete response with Pomalidomide-based as 3rd line. ORR was 53% with 16% ≥ VGPR including 1 CR for Pomalidomide-based as 4th line. With a median follow-up of 24 months, 58% and 48% at relapsed and died, respectively, in 3rd line, and similarly, 74% and 50% in 4th line. The median TTP was 7 (CI95% 1.4;12.6) and 9 (6.1;11.9) months in 3rd and 4th line, and the median OS 17 (7.8;26.1) and 23 (12.6;33.4) months, respectively. 22% and 30% have discontinued and reduced pomalidomide-based treatment respectively. No patient died related to adverse events. AEs leading to pomalidomide-based modification in schema included hematological AEs in 40% and non-hematological AEs in 12% of patients. Overall, the most common adverse events grade 3 or 4 were neutropenia (22%), anemia (11%), thrombocytopenia (7%) and infectious disease (5%).

Conclusion

Pomalidomide-based therapy demonstrates efficacy in the real life with a manageable safety profile. Further study ill look into triplet versus doublet pomalidomide-based regimen, with a benefit expected for the former. Further prospective studies are warranted to confirm this data on a larger MM population.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Myeloma, Refractory, Relapse, Treatment

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies